Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review
Intrahepatic cholangiocarcinoma (ICC) is one of the most common invasive malignant tumors, with a 5-year survival rate of less than 5%. Currently, radical surgical resection is the preferred treatment for ICC. However, most patients are only diagnosed at an advanced stage and are therefore not eligi...
Gardado en:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Immunology |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1230261/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|